Diagnostics firm Dako enters collaboration deal with AstraZeneca  

Danish cancer diagnostics company Dako has entered a collaboration agreement with AstraZeneca to develop diagnostics tests
Danish cancer diagnostics company Dako has entered a collaboration with AstraZeneca, one of the world's leading pharmaceutical companies, to develop diagnostics tests for multiple Astra Zeneca oncology projects, writes Dako in a press release. The financial terms of the deal have not been disclosed.
The companies will work together to develop diagnostics tests to help physicians determine the most appropriate cancer treatment for patients.
In the last two years, Dako has made five similar agreements with companies including Bristol Myer-Squibb and US biotech firm Genentech, which is part of the Swiss pharmaceutical giant Roche.
Lars Holmkvist, CEO of Dako told national daily newspaper Berlingske Tidende: "We are already busy with the agreements we have entered, but we have the capacity to enter more. These are collaborations on promising products seen from our side. We expect significant growth in the area and expect to enter more collaborations during the next 24 months."
Dako is a global leader in tissue-based cancer diagnostics. The company employs about 1,000 people and operates in more than 70 countries. Dako is owned by private equity fund EQT.
Link > Dako  

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×